Budget impact analysis guidelines : guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.: H82-49/2020E-PDF
"Budget impact analyses (BIAs) are used to predict and understand the potential financial impact of introducing a new pharmaceutical into a drug reimbursement system that has finite financial resources. While BIAs focus on the financial impact of the new drug, the value to the overall healthcare system is examined through other economic analyses, such as cost-effectiveness analyses (CEAs). In Canada, BIAs are used to make informed reimbursement decisions. These Guidelines provide a standardized approach and detailed recommendations for developing a BIA for submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) or to one of the participating federal/provincial/territorial (FPT) drug plans"--Introduction, page 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.885893&sl=0
| Department/Agency | Canada. Patented Medicine Prices Review Board, issuing body. |
|---|---|
| Title | Budget impact analysis guidelines : guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Earlier edition | Budget impact analysis guidelines : |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Lignes directrices pour l'analyse de l'incidence du prix d'un médicament : lignes directrices pour l'analyse de l'incidence du prix d'un médicament sur les budgets des régimes d'assurance-médicaments. "June 2020." Issued also in HTML format. Includes bibliographical references (pages 33-34). |
| Publishing information | Ottawa, ON : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, 2020. ©2020 |
| Description | 1 online resource (iv, 41 pages) |
| ISBN | 9780660345697 |
| Catalogue number |
|
| Edition | Second edition. |
| Subject terms | Drugs -- Prices -- Canada. Drugs -- Economic aspects -- Canada. Pharmaceutical services insurance -- Canada. |